查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018642

智慧切片檢查設備市場：2026-2032年全球市場預測（按產品類型、引導技術、組件、應用和最終用戶分類）

Smart Biopsy Devices Market by Product Type, Guidance Technology, Component, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，智慧切片檢查設備市場價值將達到 58.5 億美元，到 2026 年將成長至 62.2 億美元，到 2032 年將達到 91.1 億美元，複合年成長率為 6.53%。

主要市場統計數據
基準年 2025 58.5億美元
預計年份：2026年 62.2億美元
預測年份 2032 91.1億美元
複合年成長率 (%) 6.53%

本文簡要說明了診斷影像技術的創新、手術效率的提高以及臨床需求的融合如何重塑現代切片檢查設備策略。

智慧切片檢查設備的演進是臨床需求與技術能力融合的結果，需要精心的策略規劃。影像技術、針頭設計和引導軟體的進步，在提高診斷準確性的同時，也正在重塑所有醫療機構的流程。隨著臨床醫生對微創技術的需求日益成長，這些技術既能提高組織取樣的準確性，又能降低患者的風險，設備開發人員和醫療系統正積極響應，整合自動化平台，簡化規劃、導航和文件記錄流程，提供即時影像引導，並建立可互通的軟體堆疊。

技術、臨床工作流程和商業方面的重大變革正在重塑切片檢查設備的競爭定位和推廣路徑。

過去幾年，臨床實務和產品研發領域發生了翻天覆地的變化，智慧切片檢查設備的競爭格局也因此發生了根本性的改變。首先，影像引導的精準性已從輔助功能轉變為核心功能需求，推動了硬體、軟體和資料分析的深度整合。因此，製造商優先開發模組化平台，這些平台能夠接收多種影像輸入，並透過回饋迴路實現確定性的針頭定位，從而減少操作者差異。

2025 年關稅變化將對醫療設備製造和臨床導入過程中的供應鏈、採購方式和產品策略帶來壓力。

2025年公佈的關稅措施的累積影響對智慧切片檢查設備整個價值鏈的供應鏈結構和成本結構產生了切實的營運和策略影響。影響醫療設備零件和精密合金的關稅措施迫使製造商重新評估其供應商組合，加快供應商在免稅地區的認證，並考慮本地組裝以降低不斷上漲的接收成本。在許多情況下，由於企業需要對沖供應中斷和財務不確定性，這些調整導致專案管理負擔加重和庫存增加。

基於詳細細分的分析揭示了產品、應用、指導技術、最終用戶和組件的差異如何影響臨床和商業性路徑。

細分市場分析提供了一種系統性的觀點，用於識別臨床需求、技術能力和商業性機會的交集。根據產品類型，市場參與企業將其產品分為「自動化平台」和「手動平台」。自動化帶來工作流程的一致性，而手動設備則為許多操作者提供熟悉的操作體驗。這種二元性會影響產品設計和培訓投入，因為自動化解決方案需要軟硬體的緊密整合，而手動平台則更注重人體工學和觸覺回饋。

區域趨勢和策略挑戰：這重點介紹了臨床重點、法規和基礎設施如何影響全球市場的設備部署。

區域趨勢揭示了獨特的臨床重點、法規環境和採購行為，這些因素會影響部署模式和夥伴關係策略。在美洲，醫療服務體系的特點是高度專業化、擁有先進的影像基礎設施，並高度重視微創診斷途徑。這些因素有利於那些展現出高效操作、報銷相容性以及與現有影像平台互通性的醫療設備。此外，支付方的成本意識和醫院的預算週期通常也會影響採購時機以及高成本整合解決方案的採用。

透過臨床證據、綜合服務和可擴展的商業化模式，打造競爭格局和夥伴關係關係，從而脫穎而出。

智慧切片檢查領域的競爭動態由眾多參與者共同塑造，其中包括成熟的醫療設備製造商、影像系統供應商、專注於特定Start-Ups需求的敏捷型新創公司，以及提供導航和分析功能的軟體公司。這些參與者透過提供臨床證據、系統整合、售後服務和策略夥伴關係關係來脫穎而出。能夠展現明確療效優勢的公司，例如降低併發症發生率、提高診斷準確率或提升工作流程效率，往往能夠與醫療機構建立更牢固的合作關係，並獲得更優厚的合約待遇。

為製造商和醫療保健領導者提供切實可行的多方面建議，以確保供應鏈的韌性、臨床有效性和永續的商業性差異化。

產業領導者應採取多管齊下的策略，兼顧短期業務永續營運和長期平台差異化。首先，為降低貿易政策波動風險並縮短關鍵零件的前置作業時間，他們應在經濟可行的範圍內優先考慮供應鏈多元化和近岸外包。此外，還必須輔以嚴格的供應商篩選流程和情境規劃，以確保針頭和診斷影像配件等大量耗材的持續供應。

我們嚴謹的混合方法研究框架，結合了對臨床醫生的訪談、供應鏈分析、監管審查和專家檢驗，確保了可靠且可操作的見解。

本研究途徑融合了定性和定量方法，旨在全面檢驗市場動態、臨床應用促進因素和競爭優勢。初步研究包括對放射科、介入性腫瘤科和泌尿系統等不同專科的臨床醫生以及醫院、門診手術中心和診斷中心的採購經理進行結構化訪談，以收集關於醫療設備需求、工作流程限制和採購標準的第一手觀點。除訪談外，還與醫療設備工程師、監管專家和零件供應商進行了討論，以明確研發進度和採購考量。

對決定哪種切片檢查設備策略能夠帶來持續的臨床應用和商業性成功的臨床、技術和策略因素進行簡潔的整合。

總而言之，智慧切片檢查設備的演進反映了向整合式手術解決方案的廣泛轉變，這種解決方案融合了精準引導、最佳化的工作流程和軟體驅動的價值創造。臨床上對微創和高精度取樣的需求，以及影像和導航技術的進步，為能夠滿足不同應用和臨床環境需求的差異化平台創造了機會。同時，關稅變化和區域監管差異等外部壓力迫使製造商重組其供應鏈和經營模式，以維持獲利能力並確保向臨床機構不間斷供應。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：智慧切片檢查設備市場：依產品類型分類

  • 自動的
  • 手動的

第9章 智慧切片檢查設備市場指南（依技術分類）

  • CT引導
  • 磁共振引導
  • 超音波引導

第10章：智慧切片檢查設備市場：按組件分類

  • 配件
  • 導航軟體
  • 影像系統
  • 針
    • 厚直徑
    • 中型軌距
    • 細直徑

第11章 智慧切片檢查設備市場：按應用領域分類

  • 胸部
  • 肝
  • 肺
  • 攝護腺

第12章 智慧切片檢查設備市場：依最終用戶分類

  • 門診手術中心
  • 診所
  • 診斷中心
  • 醫院

第13章：智慧切片檢查設備市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 智慧切片檢查設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 智慧切片檢查設備市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國智慧切片檢查設備市場

第17章：中國智慧切片檢查設備市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Angiotech Pharmaceuticals, Inc.
  • Argon Medical Devices, Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • CONMED Corporation
  • Cook Group Incorporated
  • Danaher Corporation
  • DTR Medical Ltd. by Innovia Medical
  • Fujifilm Holdings Corporation
  • Gallini Srl
  • Hologic, Inc.
  • INRAD, Inc.
  • Intact Medical Corporation
  • Integra LifeSciences Corporation
  • Leica Biosystems Nussloch GmbH
  • Medtronic PLC
  • Merit Medical Systems
  • Olympus Corporation
  • Precision Biopsy, LLC
  • Scion Medical Technologies, LLC
  • Stryker Corporation
  • TransMed7, LLC
  • TSK Laboratory Europe BV
Product Code: MRR-221461476EF5

The Smart Biopsy Devices Market was valued at USD 5.85 billion in 2025 and is projected to grow to USD 6.22 billion in 2026, with a CAGR of 6.53%, reaching USD 9.11 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.85 billion
Estimated Year [2026] USD 6.22 billion
Forecast Year [2032] USD 9.11 billion
CAGR (%) 6.53%

A concise orientation to the convergence of imaging innovation, procedural efficiency, and clinical demand reshaping modern biopsy device strategies

The smart biopsy device landscape is converging clinical necessity and technological capability in ways that demand close strategic attention. Advances in imaging modalities, needle design, and guidance software are increasing diagnostic precision while reshaping procedural workflows across care settings. As clinicians push for minimally invasive techniques with improved tissue acquisition and reduced patient risk, device developers and health systems are adapting through integration of automated platforms, real-time imaging guidance, and interoperable software stacks that streamline planning, navigation, and documentation.

Against this backdrop, regulatory scrutiny and reimbursement pathways continue to influence product development timelines and adoption curves, while supply chain resilience and component sourcing have become quasi-strategic imperatives. Stakeholders from manufacturers to hospital procurement teams must therefore balance clinical performance with manufacturability, cost, and post-market support. In addition, the cross-pollination of innovations from adjacent imaging and surgical navigation markets is accelerating feature sets and creating new business models centered on analytics and outcomes tracking.

Taken together, these dynamics underscore the importance of a focused executive-level synthesis that highlights both the near-term operational levers and the longer-term strategic bets. The aim is to provide decision-makers with a concise yet comprehensive orientation to the forces shaping device evolution, adoption drivers across clinical settings, and the competitive responses required to maintain advantage in an increasingly sophisticated ecosystem.

Critical technological, clinical workflow, and commercial shifts that are remaking competitive positioning and adoption pathways for biopsy devices

Over the past several years, transformative shifts have accelerated in clinical practice and product development, producing a fundamentally different competitive landscape for smart biopsy devices. First, imaging-guided precision has moved from adjunctive support to a core functional requirement, driving deeper integration between hardware, software, and data analytics. As a result, manufacturers are prioritizing modular platforms that can accept multiple imaging inputs and deliver deterministic needle placement with feedback loops that reduce variability across operators.

Second, workflow optimization has become a commercial differentiator. Programs that reduce procedure time, lower complication rates, and simplify documentation attract system-level adoption. Consequently, design philosophies emphasize user-centered interfaces, automated needle deployment options, and cloud-enabled documentation that support procedural standardization. Third, convergence with digital health has introduced new monetizable services-software-as-a-service models, image analytics subscriptions, and outcome-tracking modules-that augment device revenue and deepen customer relationships.

Finally, competitive dynamics are changing as well. Smaller agile entrants are pursuing niche clinical applications and novel needle geometries, while established medtech firms leverage scale to bundle devices, imaging systems, and service contracts. Partnerships between imaging providers, software developers, and procedural device manufacturers are increasingly common, reflecting a recognition that integrated solutions win in complex clinical pathways. Altogether, these shifts demand that stakeholders rethink product roadmaps, clinical validation strategies, and go-to-market models to capture both clinical value and economic upside.

How 2025 tariff shifts have pressured supply chains, procurement behavior, and product strategies across device manufacturing and clinical adoption pathways

The cumulative impact of tariff actions announced in 2025 has introduced tangible operational and strategic consequences for supply chain configurations and cost structures across the smart biopsy device value chain. Tariff measures affecting medical device components and precision alloys have compelled manufacturers to re-evaluate supplier portfolios, accelerate supplier qualification in tariff-exempt jurisdictions, and consider localized assembly to mitigate increased landed costs. In many cases, these adjustments introduced project management overhead and inventory build-up as firms sought to hedge against supply interruptions and fiscal uncertainty.

Moreover, the tariff environment has influenced procurement behaviors among end users. Hospitals and diagnostic centers facing constrained capital budgets have heightened scrutiny on total cost of ownership, which includes not only acquisition cost but also maintenance, consumables, and the downstream operational impact of device selection. In response, vendors have emphasized transparency around component sourcing and lifecycle costs, and some have proposed alternative commercial terms-such as consumable bundling or service-inclusive agreements-to maintain competitiveness.

From a product innovation perspective, the tariff landscape has accelerated two notable responses. One, developers are exploring design simplification and material substitution where clinically acceptable, reducing reliance on high-tariff inputs. Two, companies are prioritizing differentiation through software and service layers that are less exposed to tariff fluctuations, thereby protecting margins and preserving value capture. Transitioning manufacturing footprints and diversifying supplier bases will remain an active management priority as firms seek to balance regulatory compliance, cost stability, and uninterrupted clinical supply.

Deep segmentation-driven analysis revealing how product, application, guidance technology, end-user, and component distinctions shape clinical and commercial pathways

Segmentation analysis provides a structured lens for identifying where clinical need, technological capability, and commercial opportunity intersect. Based on Product Type, market participants differentiate offerings between Automated and Manual platforms, with automation delivering workflow consistency and manual devices offering procedural familiarity for many operators. This dichotomy informs both product design and training investments, as automated solutions require tighter software-hardware integration while manual platforms prioritize ergonomics and tactile feedback.

Based on Application, clinical focus areas span Breast, Liver, Lung, and Prostate procedures, each presenting distinct anatomic and procedural constraints that shape device requirements. Breast biopsies emphasize cosmetic outcomes and outpatient procedural efficiency; liver and lung procedures demand robust imaging guidance to navigate respiratory motion and tissue heterogeneity; prostate biopsies require high spatial accuracy to align diagnostic sampling with targeted therapy planning. These application-specific imperatives drive needle design, imaging compatibility, and clinical training curricula.

Based on Guidance Technology, devices are evaluated across CT Guided, MRI Guided, and Ultrasound Guided modalities. CT guidance offers high-resolution anatomic localization in thoracic and hepatic interventions, MRI guidance excels in soft-tissue contrast and targeted prostate procedures, and ultrasound guidance provides real-time feedback and cost-effective portability. Interoperability across these guidance technologies is increasingly important as institutions seek flexible platforms that can be deployed across multiple procedure types.

Based on End User, adoption occurs across Ambulatory Surgical Centers, Clinics, Diagnostic Centers, and Hospitals, each with unique procurement cycles, staffing models, and throughput expectations. Ambulatory surgical centers and diagnostic centers often prioritize throughput and per-procedure cost efficiency, while hospitals focus on integration with broader imaging fleets and cross-departmental support. Clinics may value compact footprint and ease of use for office-based procedures.

Based on Component, device ecosystems are comprised of Accessories, Guidance Software, Imaging Systems, and Needles. Needles are further categorized across Large Gauge, Medium Gauge, and Small Gauge variants to accommodate different tissue types, sample volume needs, and clinician preferences. Component-level differentiation-such as needle lumen design, software navigation fidelity, and accessory ergonomics-drives clinician choice and impacts re-order cycles for consumables. By mapping segmentation layers to clinical workflows, stakeholders can better prioritize R&D investments and commercialization strategies that align with end-user economics and procedural outcomes.

Comparative regional dynamics and strategic imperatives highlighting how clinical priorities, regulation, and infrastructure influence device adoption across global markets

Regional dynamics exhibit distinct clinical priorities, regulatory environments, and procurement behaviors that influence adoption patterns and partnership strategies. In the Americas, healthcare delivery systems are characterized by a high degree of specialization, advanced imaging infrastructure, and a strong emphasis on minimally invasive diagnostic pathways. These factors favor devices that demonstrate procedural efficiency, reimbursement alignment, and interoperability with existing imaging platforms. Moreover, payer sensitivity and hospital budget cycles often dictate procurement timing and the uptake of higher-cost integrated solutions.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and varied capital intensity produce differentiated adoption timelines across subregions. Established markets in Western Europe prioritize conformity with stringent regulatory and safety standards, while emerging markets within the region focus on cost-effective solutions and scalable training models. Middle Eastern and African markets often present opportunities for partnership-based distribution models and localized servicing agreements, reflecting logistical complexities and diverse clinical infrastructure.

In the Asia-Pacific region, rapid investment in imaging capacity and a growing emphasis on early detection and minimally invasive care are catalyzing demand for devices that can be rapidly deployed and supported at scale. Several APAC markets are also notable for fast adoption of novel procedural workflows and for demand-driven customization to local clinical practices. Cross-border supply chain considerations and regional trade agreements further influence sourcing decisions, as manufacturers weigh proximity to growing centers of demand against manufacturing cost advantages. Overall, regional strategy must be adaptive, combining regulatory pathway planning with tailored commercial models that reflect local payer systems, clinical practice patterns, and infrastructure maturity.

Competitive landscape and partnership strategies that differentiate leaders through clinical evidence, integrated services, and scalable commercialization models

Competitive dynamics in the smart biopsy domain are shaped by a mix of established medical device firms, imaging system providers, nimble startups focused on niche procedural needs, and software-first companies that deliver navigation and analytics capabilities. These players differentiate through clinical evidence generation, system integration, after-sales service, and strategic partnerships. Firms that can demonstrate clear outcomes advantages-reduced complication rates, higher diagnostic yield, or improved workflow efficiency-tend to build stronger institutional relationships and justify premium contracting models.

In addition to product differentiation, route-to-market execution is a critical determinant of commercial success. Sales channel structures range from direct hospital partnerships and integrated imaging sales to distributor networks serving ambulatory and clinic environments. Service offerings that include training, maintenance, and consumable supply management are increasingly central to customer retention, and companies that align commercial incentives with clinical outcomes find it easier to negotiate value-based contracts.

Technology alliances are another key vector for competitive advantage. Collaborations with imaging manufacturers, cloud analytics providers, and clinical research networks accelerate time-to-evidence and broaden addressable use cases. Meanwhile, intellectual property around needle tip geometry, navigation algorithms, and software workflows creates defensive moats. The most resilient companies combine product excellence with scalable service models and a clear playbook for clinical validation across different procedure types and care settings.

Actionable multi-dimensional recommendations for manufacturers and healthcare leaders to secure supply resilience, clinical validation, and sustainable commercial differentiation

Industry leaders should adopt a multipronged strategy that balances near-term operational resilience with long-term platform differentiation. First, prioritize supply chain diversification and nearshoring where economically feasible to reduce exposure to trade policy volatility and to shorten lead times for critical components. This step should be accompanied by rigorous supplier qualification processes and scenario planning to maintain continuity for high-volume consumables such as needles and imaging accessories.

Second, invest in clinical evidence generation that aligns with the most commercially meaningful applications. Targeted prospective studies in breast, lung, liver, and prostate procedures that measure diagnostic yield, complication rates, and workflow efficiency will accelerate payer acceptance and hospital procurement decisions. Pair these studies with real-world evidence captured through integrated software to demonstrate longitudinal value.

Third, design modular platforms that enable cross-modal compatibility with CT, MRI, and ultrasound guidance. Such interoperability increases platform utilization across departments and improves return on capital for purchasers. Complement product modularity with flexible commercial models-leasing, outcome-based contracts, and bundled consumables-to address diverse purchasing preferences across hospitals, diagnostic centers, clinics, and ambulatory surgical centers.

Fourth, accelerate digital strategy by embedding guidance software, analytics, and remote support capabilities into product offerings. Digital features not only enhance procedural accuracy but also create recurring revenue pathways that are less sensitive to component tariffs. Finally, cultivate targeted channel partnerships and service infrastructures to ensure rapid deployment and high uptime in key regional markets, thereby strengthening customer loyalty and competitive differentiation.

A rigorous mixed-methods research framework that blends clinician interviews, supply chain analysis, regulatory review, and expert validation to ensure robust actionable insights

The research approach integrates qualitative and quantitative methods designed to triangulate market dynamics, clinical adoption drivers, and competitive positioning. Primary research included structured interviews with clinicians across specialties-radiology, interventional oncology, and urology-alongside procurement leaders at hospitals, ambulatory surgical centers, and diagnostic centers to capture firsthand perspectives on device requirements, workflow constraints, and purchasing criteria. These interviews were complemented by discussions with device engineers, regulatory specialists, and component suppliers to map development timelines and sourcing considerations.

Secondary research entailed systematic review of clinical literature, regulatory filings, and publicly available technical documentation to validate clinical claims and device feature sets. Where helpful, procedural guidelines and best-practice statements were synthesized to contextualize clinical utility. Data triangulation techniques were used to reconcile differing inputs, and sensitivity analysis framed how operational changes-such as tariff-driven cost pressures or shifts in reimbursement policy-could alter procurement calculus.

Throughout the process, findings were validated via expert panels comprising clinicians, health system administrators, and industry strategists to ensure pragmatic relevance. The methodology emphasizes transparency in assumptions, traceability of sources, and reproducibility of analytical steps so that stakeholders can apply insights directly to product planning, clinical trials design, and go-to-market execution.

A concise synthesis of clinical, technological, and strategic drivers that will determine which biopsy device strategies translate into sustained clinical adoption and commercial success

In summary, the evolution of smart biopsy devices reflects a broader shift toward integrated procedural solutions that combine precision guidance, optimized workflows, and software-enabled value capture. Clinical demand for minimally invasive, high-fidelity sampling is intersecting with technological progress in imaging and navigation, producing opportunities for differentiated platforms that can serve multiple applications and clinical environments. At the same time, external pressures-such as tariff changes and regional regulatory variation-are compelling manufacturers to reorient supply chains and commercial models to preserve margin and ensure uninterrupted clinical supply.

Moving forward, success will accrue to organizations that can demonstrate measurable clinical benefits, provide flexible commercial options tailored to diverse end users, and embed software-driven services that enhance procedural outcomes and create recurring revenue. The interplay between segmentation choices-product type, application, guidance technology, end-user, and component design-and regional strategy will determine which offerings scale effectively. For decision-makers, the imperative is to align R&D priorities with validated clinical needs, operational realities, and adaptable go-to-market tactics so that innovations translate into sustainable clinical adoption and long-term institutional partnerships.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Smart Biopsy Devices Market, by Product Type

  • 8.1. Automated
  • 8.2. Manual

9. Smart Biopsy Devices Market, by Guidance Technology

  • 9.1. CT Guided
  • 9.2. MRI Guided
  • 9.3. Ultrasound Guided

10. Smart Biopsy Devices Market, by Component

  • 10.1. Accessories
  • 10.2. Guidance Software
  • 10.3. Imaging Systems
  • 10.4. Needles
    • 10.4.1. Large Gauge
    • 10.4.2. Medium Gauge
    • 10.4.3. Small Gauge

11. Smart Biopsy Devices Market, by Application

  • 11.1. Breast
  • 11.2. Liver
  • 11.3. Lung
  • 11.4. Prostate

12. Smart Biopsy Devices Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
  • 12.3. Diagnostic Centers
  • 12.4. Hospitals

13. Smart Biopsy Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Smart Biopsy Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Smart Biopsy Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Smart Biopsy Devices Market

17. China Smart Biopsy Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Angiotech Pharmaceuticals, Inc.
  • 18.6. Argon Medical Devices, Inc.
  • 18.7. B. Braun Melsungen AG
  • 18.8. Becton, Dickinson and Company
  • 18.9. Boston Scientific Corporation
  • 18.10. Cardinal Health, Inc.
  • 18.11. CONMED Corporation
  • 18.12. Cook Group Incorporated
  • 18.13. Danaher Corporation
  • 18.14. DTR Medical Ltd. by Innovia Medical
  • 18.15. Fujifilm Holdings Corporation
  • 18.16. Gallini Srl
  • 18.17. Hologic, Inc.
  • 18.18. INRAD, Inc.
  • 18.19. Intact Medical Corporation
  • 18.20. Integra LifeSciences Corporation
  • 18.21. Leica Biosystems Nussloch GmbH
  • 18.22. Medtronic PLC
  • 18.23. Merit Medical Systems
  • 18.24. Olympus Corporation
  • 18.25. Precision Biopsy, LLC
  • 18.26. Scion Medical Technologies, LLC
  • 18.27. Stryker Corporation
  • 18.28. TransMed7, LLC
  • 18.29. TSK Laboratory Europe BV

LIST OF FIGURES

  • FIGURE 1. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SMART BIOPSY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SMART BIOPSY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES SMART BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA SMART BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY AUTOMATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY AUTOMATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY CT GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY CT GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY CT GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY MRI GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY MRI GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY MRI GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY ULTRASOUND GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY ULTRASOUND GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY ULTRASOUND GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY LARGE GAUGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY LARGE GAUGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY LARGE GAUGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY MEDIUM GAUGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY MEDIUM GAUGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY MEDIUM GAUGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY SMALL GAUGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY SMALL GAUGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY SMALL GAUGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY BREAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY BREAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY BREAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY LIVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY LIVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY LUNG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY LUNG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS SMART BIOPSY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GCC SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GCC SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. GCC SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. GCC SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 137. GCC SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 138. GCC SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. GCC SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. G7 SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. G7 SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. G7 SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. G7 SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 158. G7 SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 159. G7 SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. G7 SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NATO SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. NATO SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NATO SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. NATO SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 165. NATO SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 166. NATO SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. NATO SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES SMART BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA SMART BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)